264 related articles for article (PubMed ID: 9633877)
1. Iron chelators for thalassaemia.
Hershko C; Konijn AM; Link G
Br J Haematol; 1998 Jun; 101(3):399-406. PubMed ID: 9633877
[No Abstract] [Full Text] [Related]
2. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy of iron overload in thalassaemic patients.
Ceci A; Felisi M; De Sanctis V; De Mattia D
Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
[TBL] [Abstract][Full Text] [Related]
4. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
[TBL] [Abstract][Full Text] [Related]
5. Iron chelation with oral deferiprone in patients with thalassemia.
Cohen AR; Martin MB
N Engl J Med; 1998 Dec; 339(23):1713-4. PubMed ID: 9867542
[No Abstract] [Full Text] [Related]
6. The effectiveness of deferiprone in thalassemia.
Dogherty P; Einarson T; Koren G; Sher G
Blood; 1997 Jul; 90(2):894. PubMed ID: 9226195
[No Abstract] [Full Text] [Related]
7. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Kontoghiorghes GJ
Expert Opin Emerg Drugs; 2006 Mar; 11(1):1-5. PubMed ID: 16503822
[TBL] [Abstract][Full Text] [Related]
8. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
9. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
10. Deferiprone for thalassaemia.
Kontoghiorghes GJ; Agarwal MB; Grady RW; Kolnagou A; Marx JJ
Lancet; 2000 Jul; 356(9227):428-9. PubMed ID: 10972396
[No Abstract] [Full Text] [Related]
11. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Peng CT; Tsai CH; Wu KH
Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
[TBL] [Abstract][Full Text] [Related]
12. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
Aydinok Y; Nisli G; Kavakli K
Br J Haematol; 1999 Jul; 106(1):252-3. PubMed ID: 10444196
[No Abstract] [Full Text] [Related]
13. [Iron chelation in 1998].
de Montalembert M
Transfus Clin Biol; 1998 Oct; 5(5):353-6. PubMed ID: 9836396
[TBL] [Abstract][Full Text] [Related]
14. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
Smith GC; Alpendurada F; Carpenter JP; Alam MH; Berdoukas V; Karagiorga M; Ladis V; Piga A; Aessopos A; Gotsis ED; Tanner MA; Westwood MA; Galanello R; Roughton M; Pennell DJ
J Cardiovasc Magn Reson; 2011 Jul; 13(1):34. PubMed ID: 21733147
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
Piga A; Gaglioti C; Fogliacco E; Tricta F
Haematologica; 2003 May; 88(5):489-96. PubMed ID: 12745268
[TBL] [Abstract][Full Text] [Related]
16. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
Kontoghiorghes GJ; Neocleous K; Kolnagou A
Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
18. Do we need more iron-chelating drugs?
Kontoghiorghes GJ
Lancet; 2003 Aug; 362(9382):495-6. PubMed ID: 12927446
[No Abstract] [Full Text] [Related]
19. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
20. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
